This approval, for its Enoxaparin product in pre-filled syringes, comes from the largest pharmaceutical market in the Gulf Cooperation Council (GCC) region. This market is projected to grow to USD 13.1 billion by 2031, with a 10-year CAGR of 5.4 per cent.

According to the quarterly results, the net sales decreased by 6.79 per cent to Rs 1,702 crore, operating profit increased by 33.33 per cent to Rs 132 crore and net profit increased by 9.30 per cent to Rs 47 crore in Q1FY24 compared to Q1FY23. In FY23, the net sales increased by 64.69 per cent to Rs 6,927 crore and net profit increased by 47.74 per cent to Rs 164 crore compared to FY22.

The total renewables capacity of TPREL stands at 7,821 MW including 3,689 MW projects under various stages of implementation. The company's operational capacity is 4,132 MW, which includes 3,139 MW solar and 993 MW wind.

Today, on the 9th day after the investment, the closing price of each share is Rs 279.25. As a result, the total value of the shares he owns is Rs 28,88,43,076.

Shares of the company have jumped more than 130 per cent in the last 6 months.

The stock saw a spurt in volume by more than 2.07 times.

The stock saw a spurt in volume by more than 4.28 times.

The stock saw a spurt in Volume by more than 1.03 times.

Sharma to become Paytm's largest shareholder with 19.42 per cent stake, Antfin's ownership down to 13.5 per cent.

The share saw a spurt in volume of 2.89 times on BSE.